ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

JANX Janux Therapeutics Inc

47.39
0.29 (0.62%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Janux Therapeutics Inc JANX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.29 0.62% 47.39 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
47.08 46.51 48.23 47.39 47.10
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/3/202415:47EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/3/202415:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202415:11EDGAR2Form 8-K - Current report
08/3/202415:01BWJanux Therapeutics Reports Fourth Quarter and Full Year 2023..
29/2/202416:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202416:11EDGAR2Form 8-K - Current report
29/2/202400:22BWJanux Therapeutics Announces Pricing of $296.5 Million..
28/2/202420:55EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/2/202416:15EDGAR2Form 8-K - Current report
27/2/202420:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202416:23EDGAR2Form 8-K - Current report
27/2/202416:00BWJanux Therapeutics Announces Proposed Public Offering of..
26/2/202415:05BWJanux Announces Encouraging Safety and Efficacy Data in..
20/2/202407:00BWJanux Therapeutics to Host Virtual Event Discussing Updated..
09/2/202415:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202415:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202408:00BWJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo,..
03/1/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:45EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/11/202315:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:07EDGAR2Form 8-K - Current report
07/11/202315:01BWJanux Therapeutics Reports Third Quarter 2023 Financial..
07/9/202317:14EDGAR2Form 144 - Report of proposed sale of securities
14/8/202315:33EDGAR2Form 144 - Report of proposed sale of securities
08/8/202315:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:17EDGAR2Form 8-K - Current report
08/8/202315:01BWJanux Therapeutics Reports Second Quarter 2023 Financial..
18/7/202316:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/7/202315:16EDGAR2Form 8-K - Current report
17/7/202307:45BWJanux Therapeutics Announces Pricing of $60 Million..
17/7/202307:16EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
17/7/202307:06EDGAR2Form 8-K - Current report
17/7/202307:00BWJanux Therapeutics Announces Positive Interim Clinical Data..
05/6/202315:35BWJanux Therapeutics Appoints Zachariah McIver, D.O., Ph.D.,..
09/5/202315:01BWJanux Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock